These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26475253)

  • 1. What happens in the skin? Integrating skin permeation kinetics into studies of developmental and reproductive toxicity following topical exposure.
    Dancik Y; Bigliardi PL; Bigliardi-Qi M
    Reprod Toxicol; 2015 Dec; 58():252-81. PubMed ID: 26475253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of bioavailability: measurement of absorption through skin in vitro.
    Hotchkiss SA
    Curr Protoc Toxicol; 2001 May; Chapter 5():Unit 5.1.1-14. PubMed ID: 20949434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical and pharmacokinetic modelling of epidermal and dermal transport processes.
    Anissimov YG; Jepps OG; Dancik Y; Roberts MS
    Adv Drug Deliv Rev; 2013 Feb; 65(2):169-90. PubMed ID: 22575500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modest but increased penetration through damaged skin: an overview of the in vivo human model.
    Gattu S; Maibach HI
    Skin Pharmacol Physiol; 2011; 24(1):2-9. PubMed ID: 20588085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of the dermal route of exposure to risk assessment.
    Mattie DR; Grabau JH; McDougal JN
    Risk Anal; 1994 Jun; 14(3):277-84. PubMed ID: 8029499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vesicles as tools for the modulation of skin permeability.
    Dubey V; Mishra D; Nahar M; Jain NK
    Expert Opin Drug Deliv; 2007 Nov; 4(6):579-93. PubMed ID: 17970662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Göttingen minipigs for Prediction of Human Pharmacokinetic Profiles After Dermal Drug Application.
    Yamamoto S; Karashima M; Sano N; Fukushi C; Tohyama K; Arai Y; Hirabayashi H; Amano N
    Pharm Res; 2017 Nov; 34(11):2415-2424. PubMed ID: 28828717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption.
    Wester RC; Maibach HI
    Drug Metab Rev; 1983; 14(2):169-205. PubMed ID: 6341024
    [No Abstract]   [Full Text] [Related]  

  • 10. Design and performance of a spreadsheet-based model for estimating bioavailability of chemicals from dermal exposure.
    Dancik Y; Miller MA; Jaworska J; Kasting GB
    Adv Drug Deliv Rev; 2013 Feb; 65(2):221-36. PubMed ID: 22285584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced absorption through damaged skin: an overview of the in vitro human model.
    Gattu S; Maibach HI
    Skin Pharmacol Physiol; 2010; 23(4):171-6. PubMed ID: 20185974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of formulations and experimental conditions on in vitro human skin permeation-Data from updated EDETOX database.
    Samaras EG; Riviere JE; Ghafourian T
    Int J Pharm; 2012 Sep; 434(1-2):280-91. PubMed ID: 22634139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Humidity on In Vitro Human Skin Permeation Experiments for Predicting In Vivo Permeability.
    Ishida M; Takeuchi H; Endo H; Yamaguchi JI
    J Pharm Sci; 2015 Dec; 104(12):4223-4231. PubMed ID: 26461468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of pharmacokinetics in designing toxicological protocols and improving interspecies extrapolation.
    Young JF; Holson JF
    J Environ Pathol Toxicol; 1978; 2(1):169-86. PubMed ID: 722219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption.
    Polak S; Ghobadi C; Mishra H; Ahamadi M; Patel N; Jamei M; Rostami-Hodjegan A
    J Pharm Sci; 2012 Jul; 101(7):2584-95. PubMed ID: 22517028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in skin mimic systems to predict transdermal permeation.
    Waters LJ
    Curr Pharm Des; 2015; 21(20):2725-32. PubMed ID: 25925123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative structure-skin permeability relationships.
    Tsakovska I; Pajeva I; Al Sharif M; Alov P; Fioravanzo E; Kovarich S; Worth AP; Richarz AN; Yang C; Mostrag-Szlichtyng A; Cronin MTD
    Toxicology; 2017 Jul; 387():27-42. PubMed ID: 28645577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic and empirical modeling of skin permeation of drugs.
    Yamashita F; Hashida M
    Adv Drug Deliv Rev; 2003 Sep; 55(9):1185-99. PubMed ID: 12954198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defense against dermal exposures is only skin deep: significantly increased penetration through slightly damaged skin.
    Nielsen JB; Nielsen F; Sørensen JA
    Arch Dermatol Res; 2007 Nov; 299(9):423-31. PubMed ID: 17882442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.